Henry Schein Looks Bullish (Technical Analysis)
HSIC shows bullish price action, momentum, volume, and relative strength, making it an attractive investment with a 2.6 reward-to-risk ratio. The stock is in an uptrend, trading above its 30-week EMA, and has bullish short-term and long-term momentum as indicated by the PPO. Institutional buying supports bullish volume trends, and HSIC has been outperforming the S&P 500 since December 2024.
Henry Schein: An Industry Leader That Offers Some Upside From Here
Henry Schein is the world's largest provider of healthcare products and services for office-based dental and medical practitioners, showing consistent growth through acquisitions. Despite a 3% dip in shares, management's 2025 guidance indicates continued growth, justifying a bullish stance on the stock. The firm reported a 5.8% revenue increase in Q4 2024, driven by organic growth and acquisitions, with significant improvements in net income and operating cash flow.
Henry Schein, Inc. (HSIC) Q4 2024 Earnings Call Transcript
Henry Schein, Inc. (NASDAQ:HSIC ) Q4 2024 Earnings Conference Call February 25, 2025 8:00 AM ET Company Participants Graham Stanley - Vice President of Investor Relations & Strategic Financial Project Officer Stanley Bergman - Chairman & Chief Executive Officer Ronald South - Senior Vice President & Chief Financial Officer Conference Call Participants Jason Bednar - Piper Sandler Jeffrey Johnson - Baird Allen Lutz - Bank of America John Stansel - JPMorgan Jonathan Block - Stifel Kevin Caliendo - UBS Brandon Vazquez - William Blair Elizabeth Anderson - Evercore ISI Operator Good morning ladies and gentlemen and welcome to Henry Schein's Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
HSIC Q4 Earnings Match Estimates, Margins Up, Stock Falls in Premarket
Henry Schein's fourth-quarter results reflect stable dental and medical end-markets.
Henry Schein Q4 Earnings And Outlook Miss Expectations, Restructures For Growth
On Tuesday, Henry Schein Inc. HSIC reported a fourth-quarter adjusted EPS of $1.19, up 80.3% year-over-year, missing the consensus of $1.21.
Henry Schein (HSIC) Meets Q4 Earnings Estimates
Henry Schein (HSIC) came out with quarterly earnings of $1.19 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.66 per share a year ago.
Henry Schein forecasts 2025 profit below estimates on weak demand for dental products
Henry Schein forecast annual profit below Wall Street estimates on Tuesday as the dental and medical products distributor faces tepid demand amid persistent inflation.
Unveiling Henry Schein (HSIC) Q4 Outlook: Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Henry Schein (HSIC), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.
HSIC Gears Up for Q4 Earnings: Here's What You Need to Know
Henry Schein is expected to report impressive sales in both its businesses in the fourth quarter of 2024, along with a positive pace of recovery from the cyber incident.
Exclusive: Activist Ananym plans to launch proxy fight at Henry Schein, sources say
Activist investor Ananym Capital Management plans to nominate as many as half a dozen directors to the board at Henry Schein , arguing the dental and medical distributor needs to start searching for a new CEO, cut costs and optimize capital allocation, three sources familiar with the matter said.
HSIC Stock Might Rise Following the Acquisition of Acentus
Henry Schein completes the acquisition of Acentus, which expands the former's Home Solution business.
Henry Schein Stock to Gain From New Acquisitions Amid Macro Woes
Henry Schein has strategically set up distribution centers worldwide to better serve customers and increase its operating efficiency.
